BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol 2019;10:751-65. [PMID: 31392056 DOI: 10.21037/jgo.2019.03.10] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Ho J, Fiocco C, Spencer K. Treating Biliary Tract Cancers: New Targets and Therapies. Drugs 2022. [DOI: 10.1007/s40265-022-01808-x] [Reference Citation Analysis]
2 Rimini M, Fabregat-Franco C, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A. Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma. Sci Rep 2022;12:18775. [PMID: 36335135 DOI: 10.1038/s41598-022-22543-z] [Reference Citation Analysis]
3 Rimini M, Loi E, Fabregat-franco C, Burgio V, Lonardi S, Niger M, Scartozzi M, Raposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Rizzato M, Nichetti F, Lai E, Cappetta A, Macarulla T, Fassan M, De Braud F, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Patrizia Z, Casadei-gardini A. Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters. European Journal of Cancer 2022;175:299-310. [DOI: 10.1016/j.ejca.2022.08.026] [Reference Citation Analysis]
4 Roth GS, Neuzillet C, Sarabi M, Edeline J, Malka D, Lièvre A. Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalized medicine ? European Journal of Cancer 2022. [DOI: 10.1016/j.ejca.2022.11.006] [Reference Citation Analysis]
5 Zhang Y, Esmail A, Mazzaferro V, Abdelrahim M. Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision. Cancers 2022;14:5074. [DOI: 10.3390/cancers14205074] [Reference Citation Analysis]
6 Kanai M. Current Clinical Practice of Precision Medicine Using Comprehensive Genomic Profiling Tests in Biliary Tract Cancer in Japan. Curr Oncol 2022;29:7272-84. [PMID: 36290850 DOI: 10.3390/curroncol29100573] [Reference Citation Analysis]
7 Rimini M, Burgio V, Antonuzzo L, Rimassa L, Oneda E, Lavacchi D, Personeni N, Ratti F, Pedica F, Della Corte A, Persano M, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-gardini A. Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis. Targ Oncol. [DOI: 10.1007/s11523-022-00917-7] [Reference Citation Analysis]
8 Berchuck JE, Facchinetti F, DiToro DF, Baiev I, Majeed U, Reyes S, Chen C, Zhang K, Sharman R, Junior PLSU, Maurer J, Shroff RT, Pritchard CC, Wu MJ, Catenacci DVT, Javle M, Friboulet L, Hollebecque A, Bardeesy N, Zhu AX, Lennerz JK, Tan B, Borad M, Parikh AR, Kiedrowski LA, Kelley RK, Mody K, Juric D, Goyal L. The Clinical Landscape of Cell-Free DNA Alterations in 1,671 Patients with Advanced Biliary Tract Cancer. Ann Oncol 2022:S0923-7534(22)04141-2. [PMID: 36089135 DOI: 10.1016/j.annonc.2022.09.150] [Reference Citation Analysis]
9 Lavacchi D, Caliman E, Rossi G, Buttitta E, Botteri C, Fancelli S, Pellegrini E, Roviello G, Pillozzi S, Antonuzzo L. Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions. Pharmacology & Therapeutics 2022;237:108170. [DOI: 10.1016/j.pharmthera.2022.108170] [Reference Citation Analysis]
10 Raggi C, Taddei ML, Rae C, Braconi C, Marra F. Metabolic reprogramming in cholangiocarcinoma. J Hepatol 2022;77:849-64. [PMID: 35594992 DOI: 10.1016/j.jhep.2022.04.038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Yu H, Xu Y, Gao W, Li M, He J, Deng X, Xing W. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer. Front Oncol 2022;12:930611. [DOI: 10.3389/fonc.2022.930611] [Reference Citation Analysis]
12 Kandemir EA. Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021. J Oncol Pharm Pract 2022;:10781552221112015. [PMID: 35793068 DOI: 10.1177/10781552221112015] [Reference Citation Analysis]
13 Demols A, Bucalau AM, Mans L. The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy. Curr Opin Oncol 2022;34:403-11. [PMID: 35837710 DOI: 10.1097/CCO.0000000000000850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hewitt DB, Brown ZJ, Pawlik TM. Current Perspectives on the Surgical Management of Perihilar Cholangiocarcinoma. Cancers (Basel) 2022;14:2208. [PMID: 35565335 DOI: 10.3390/cancers14092208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Carotenuto M, Sacco A, Forgione L, Normanno N. Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2022.00079] [Reference Citation Analysis]
16 Gray S, Lamarca A, Edeline J, Klümpen H, Hubner RA, Mcnamara MG, Valle JW. Targeted Therapies for Perihilar Cholangiocarcinoma. Cancers 2022;14:1789. [DOI: 10.3390/cancers14071789] [Reference Citation Analysis]
17 Holster JJ, El Hassnaoui M, Franssen S, IJzermans JNM, de Jonge J, Mostert B, Polak WG, de Wilde RF, Homs MYV, Groot Koerkamp B. Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. Ann Surg Oncol 2022. [PMID: 35294656 DOI: 10.1245/s10434-022-11439-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Obradovic A, Tomassoni L, Yu D, Guillan K, Souto K, Fraser E, Bates S, Drake CG, Saenger Y, Cruz FD, Kung A, Califano A. Case Study of Single-cell Protein Activity Based Drug Prediction for Precision Treatment of Cholangiocarcinoma.. [DOI: 10.1101/2022.02.28.482410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Cadamuro M, Macias RI, Strain AJ, Strazzabosco M, Simioni P, Marin JJ, Fabris L. Unmet needs in basic and translational research in Cholangiocarcinoma. Liver Cancer International 2022;3:5-16. [DOI: 10.1002/lci2.39] [Reference Citation Analysis]
20 Wintheiser G, Zemla T, Shi Q, Tran N, Prasai K, Tella SH, Mody K, Ahn D, Borad M, Bekaii-Saab T, Mahipal A. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. JCO Precis Oncol 2022;6:e2100156. [PMID: 35005992 DOI: 10.1200/PO.21.00156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
21 Desai A, Borad MJ. Molecularly Targeted Therapy in Cholangiocarcinoma. The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases 2022. [DOI: 10.1007/978-981-19-0063-1_22] [Reference Citation Analysis]
22 Zarei M, Hue JJ, Hajihassani O, Graor HJ, Katayama ES, Loftus AW, Bajor D, Rothermel LD, Vaziri-Gohar A, Winter JM. Clinical development of IDH1 inhibitors for cancer therapy. Cancer Treat Rev 2021;103:102334. [PMID: 34974243 DOI: 10.1016/j.ctrv.2021.102334] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
23 De B, Abu-Gheida I, Patel A, Ng SSW, Zaid M, Thunshelle CP, Elganainy D, Corrigan KL, Rooney MK, Javle M, Raghav K, Lee SS, Vauthey JN, Tzeng CD, Tran Cao HS, Ludmir EB, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Koay EJ. Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med 2021;11:1270. [PMID: 34945742 DOI: 10.3390/jpm11121270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Adeva J. Current development and future perspective of IDH1 inhibitors in cholangiocarcinoma. Liver Cancer International 2022;3:17-31. [DOI: 10.1002/lci2.43] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Ioffe D, Phull P, Dotan E. Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review. Cancer Manag Res 2021;13:8085-98. [PMID: 34737637 DOI: 10.2147/CMAR.S276104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Tsimafeyeu I, Temper M. Cholangiocarcinoma: An Emerging Target for Molecular Therapy. Gastrointest Tumors 2021;8:153-8. [PMID: 34722468 DOI: 10.1159/000517258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
27 Prete MG, Cammarota A, D'alessio A, Zanuso V, Rimassa L. Current options and future directions of systemic therapy for advanced biliary tract cancer. Exploration of Targeted Anti-tumor Therapy 2021;2. [DOI: 10.37349/etat.2021.00054] [Reference Citation Analysis]
28 Persano M, Puzzoni M, Ziranu P, Pusceddu V, Lai E, Pretta A, Donisi C, Pinna G, Spanu D, Cimbro E, Parrino A, Liscia N, Mariani S, Dubois M, Migliari M, Scartozzi M. Molecular-driven treatment for biliary tract cancer: the promising turning point. Expert Rev Anticancer Ther 2021;21:1253-64. [PMID: 34551663 DOI: 10.1080/14737140.2021.1982699] [Reference Citation Analysis]
29 Chou FJ, Liu Y, Lang F, Yang C. D-2-Hydroxyglutarate in Glioma Biology. Cells 2021;10:2345. [PMID: 34571995 DOI: 10.3390/cells10092345] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
30 Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer.Lancet. 2021;397:428-444. [PMID: 33516341 DOI: 10.1016/S0140-6736(21)00153-7] [Cited by in Crossref: 140] [Cited by in F6Publishing: 163] [Article Influence: 140.0] [Reference Citation Analysis]
31 Katabathina VS, Marji H, Khanna L, Ramani N, Yedururi S, Dasyam A, Menias CO, Prasad SR. Decoding Genes: Current Update on Radiogenomics of Select Abdominal Malignancies. Radiographics 2020;40:1600-26. [PMID: 33001791 DOI: 10.1148/rg.2020200042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
32 Zhao S, Xu Y, Wu W, Wang P, Wang Y, Jiang H, Zhu J. ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms. Front Oncol 2021;11:693295. [PMID: 34249744 DOI: 10.3389/fonc.2021.693295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
33 Stemer G, Rowe JM, Ofran Y. Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence. Blood Lymphat Cancer 2021;11:41-54. [PMID: 34188585 DOI: 10.2147/BLCTT.S236446] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
34 Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol 2021. [PMID: 34131315 DOI: 10.1038/s41571-021-00521-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 52] [Article Influence: 43.0] [Reference Citation Analysis]
35 Corrigan L, Lowery M. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021;15:475-81. [PMID: 33836133 DOI: 10.1080/17474124.2021.1915765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Marin JJG, Sanchon-Sanchez P, Cives-Losada C, Del Carmen S, González-Santiago JM, Monte MJ, Macias RIR. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers (Basel) 2021;13:2358. [PMID: 34068398 DOI: 10.3390/cancers13102358] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
37 Angelakas A, Lamarca A, Hubner RA, McNamara MG, Valle JW. Ivosidenib: an investigational drug for the treatment of biliary tract cancers. Expert Opin Investig Drugs 2021;30:301-7. [PMID: 33683991 DOI: 10.1080/13543784.2021.1900115] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Kamp EJCA, Dinjens WNM, Doukas M, Bruno MJ, de Jonge PJF, Peppelenbosch MP, de Vries AC. Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures. Therap Adv Gastroenterol 2021;14:17562848211002023. [PMID: 33948111 DOI: 10.1177/17562848211002023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Chamberlain CX, Faust E, Goldschmidt D, Webster N, Boscoe AN, Macaulay D, Peters ML. Burden of illness for patients with cholangiocarcinoma in the United States: a retrospective claims analysis. J Gastrointest Oncol 2021;12:658-68. [PMID: 34012657 DOI: 10.21037/jgo-20-544] [Reference Citation Analysis]
40 Mehta R, Wood AC, Yu J, Kim R. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. Expert Opin Investig Drugs 2021;30:451-61. [PMID: 33660569 DOI: 10.1080/13543784.2021.1898586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
41 Aguado-Fraile E, Tassinari A, Ishii Y, Sigel C, Lowery MA, Goyal L, Gliser C, Jiang L, Pandya SS, Wu B, Bardeesy N, Choe S, Deshpande V. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma. Future Oncol 2021;17:2057-74. [PMID: 33709779 DOI: 10.2217/fon-2020-1274] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
42 Wang Z, Jin Y, Guo Y, Tan Z, Zhang X, Ye D, Yu Y, Peng S, Zheng L, Li J. Conversion Therapy of Intrahepatic Cholangiocarcinoma Is Associated with Improved Prognosis and Verified by a Case of Patient-Derived Organoid. Cancers (Basel) 2021;13:1179. [PMID: 33803322 DOI: 10.3390/cancers13051179] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
43 Perego G, Burgio V, Nozza R, Longobardo G, Bernecich M, Luciani A, Petrelli F. Is there any place for novel agents in treating biliary tract cancer? Med Oncol 2021;38:19. [PMID: 33543377 DOI: 10.1007/s12032-021-01463-4] [Reference Citation Analysis]
44 Keenan BP, Kelley RKK. Key challenges for drugs in clinical development for cholangiocarcinoma. Expert Opin Investig Drugs 2021;30:285-90. [PMID: 33530767 DOI: 10.1080/13543784.2021.1880565] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
45 Merz V, Zecchetto C, Melisi D. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. Future Oncology 2021;17:389-402. [DOI: 10.2217/fon-2020-0726] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
46 Chiang NJ, Chen LT, Shan YS, Yeh CN, Chen MH. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules 2021;11:97. [PMID: 33451059 DOI: 10.3390/biom11010097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
47 Ferrucci PF, Cocorocchio E, Bonomo G, Varano GM, Della Vigna P, Orsi F. A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System. Cells 2021;10:E70. [PMID: 33466278 DOI: 10.3390/cells10010070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
48 Kanai M. Recent Advances of Precision Medicine in Pancreatic Cancer and Cholangiocarcinoma. Management of Pancreatic Cancer and Cholangiocarcinoma 2021. [DOI: 10.1007/978-981-16-2870-2_4] [Reference Citation Analysis]
49 Sigel C, Wang T. Pathological Diagnosis of Cholangiocarcinoma. Diagnosis and Management of Cholangiocarcinoma 2021. [DOI: 10.1007/978-3-030-70936-5_8] [Reference Citation Analysis]
50 Personeni N, Lleo A, Pressiani T, Colapietro F, Openshaw MR, Stavraka C, Pouptsis A, Pinato DJ, Rimassa L. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers (Basel) 2020;12:E3370. [PMID: 33202975 DOI: 10.3390/cancers12113370] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
51 McNamara MG, Lopes A, Wasan H, Malka D, Goldstein D, Shannon J, Okusaka T, Knox JJ, Wagner AD, André T, Cunningham D, Moehler M, Jensen LH, Koeberle D, Bekaii-Saab T, Bridgewater J, Valle JW. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. J Hepatol 2020;73:1109-17. [PMID: 32446715 DOI: 10.1016/j.jhep.2020.05.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
52 Crispo F, Pietrafesa M, Condelli V, Maddalena F, Bruno G, Piscazzi A, Sgambato A, Esposito F, Landriscina M. IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives. Molecules 2020;25:E3754. [PMID: 32824685 DOI: 10.3390/molecules25163754] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
53 Chakrabarti S, Kamgar M, Mahipal A. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.Cancers (Basel). 2020;12. [PMID: 32722188 DOI: 10.3390/cancers12082039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
54 Hayashi H, Baba H. New era with the genetic assessment for biliary tree cancers beyond the anatomical assessment alone. Ann Transl Med 2020;8:732. [PMID: 32647657 DOI: 10.21037/atm.2020.03.206] [Reference Citation Analysis]
55 Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. J Hepatol 2020;73:170-85. [PMID: 32171892 DOI: 10.1016/j.jhep.2020.03.007] [Cited by in Crossref: 156] [Cited by in F6Publishing: 156] [Article Influence: 78.0] [Reference Citation Analysis]
56 Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796-807. [PMID: 32416072 DOI: 10.1016/s1470-2045(20)30157-1] [Cited by in Crossref: 347] [Cited by in F6Publishing: 376] [Article Influence: 173.5] [Reference Citation Analysis]
57 Athauda A, Fong C, Lau DK, Javle M, Abou-Alfa GK, Morizane C, Steward K, Chau I. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treat Rev 2020;86:101998. [PMID: 32203843 DOI: 10.1016/j.ctrv.2020.101998] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
58 Pastore M, Lori G, Gentilini A, Taddei ML, Di Maira G, Campani C, Recalcati S, Invernizzi P, Marra F, Raggi C. Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives. Cells 2020;9:E596. [PMID: 32138158 DOI: 10.3390/cells9030596] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
59 Lowery MA, Burris HA 3rd, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Fan B, Aguado-Fraile E, Choe S, Wu B, Gliser C, Agresta SV, Pandya SS, Zhu AX, Abou-Alfa GK. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol 2019;4:711-20. [PMID: 31300360 DOI: 10.1016/S2468-1253(19)30189-X] [Cited by in Crossref: 113] [Cited by in F6Publishing: 123] [Article Influence: 37.7] [Reference Citation Analysis]